The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback